Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 1 crawled time : 20:20 save search
Affimed Provides Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at the ASH 2022 Annual Meeting
Published: 2022-12-10 (Crawled : 20:20) - globenewswire.com
AFMD | $5.22 4.4% 4.21% 22K
|
Health Technology
| Email alert
Add to watchlist
afm13 meeting study phase 1
Positive Phase 1 Data from mRNA-based Individualized Neoantigen Specific Immunotherapy in Patients with Resected Pancreatic Cancer presented at ASCO
Published: 2022-06-05 (Crawled : 20:20) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
| Email alert
Add to watchlist
BNTX | News | $88.53 0.59% 0.59% 360K
|
Health Technology
| Email alert
Add to watchlist
immunotherapy asco positive cancer pancreatic phase 1
New REGN5458 (BCMAxCD3) Phase 1 Data Show 75% Response Rate at Highest Dose Levels Studied in Patients with Heavily Pretreated Multiple Myeloma
Published: 2021-12-11 (Crawled : 20:20) - prnewswire.com
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
| Email alert
Add to watchlist
regn5458 phase 1
4D Molecular Therapeutics Presents Interim Results from the Ongoing 4D-125 Phase 1/2 Clinical Trial in Patients with Advanced X-linked Retinitis Pigmentosa at the ASRS Annual Meeting
Published: 2021-10-10 (Crawled : 20:20) - globenewswire.com
FDMT M | $24.77 -6.14% -6.54% 570K
|
Health Technology
|
| O: -5.81%
H: 16.67%
C: 14.68%
ongoing phase 1 results molecular trial
RAPT Therapeutics to Report Top Line Data from Phase 1b Trial of RPT193 in Atopic Dermatitis
Published: 2021-06-13 (Crawled : 20:20) - globenewswire.com
RAPT | $8.0 1.78% 1.75% 330K
|
Health Technology
|
| O: 56.92%
H: 44.1%
C: 37.34%
phase 1 dermatitis trial topline atopic dermatitis phase 1b phase 2b
Prothena Presents Phase 1 Study Results of PRX004 in Oral Presentation at AAN 2021
Published: 2021-04-18 (Crawled : 20:20) - globenewswire.com
PRTA 4 | $20.565 -3.41% -3.53% 440K
|
Health Technology
|
| O: -0.68%
H: 2.23%
C: -3.73%
presentation phase 1 results phase 2 phase 3
Gainers vs Losers
| 79% | 21% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 870K
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.